About Us
Corporate Overview
Executive Leadership
Management team
Scientific Advisory Board
Board of Directors
Product Portfolio
Pipeline
Overview
AG-73305
AG-80308
AG-86893
Disease
Overview
DME
wAMD
Other Diseases
Pterygium
Dry Eye
Investor Relations
Investors
Press Release & Publications
Contact Us
News
2022-06-20
Allgenesis Announces First Patient Dosed in the U.S. for the Phase 1b trial Evaluating AG-80308 for the Treatment of Dry Eye Disease
Read more
2022-06-13
Allgenesis Announces First Patient Enrollment in a FIH Phase 2a Trial of AG-73305 for the Treatment of Diabetic Macular Edema
Read more
2022-03-31
Allgenesis Announces FDA Clearance of the IND for AG-73305 for the Treatment of Diabetic Macular Edema
Read more
2022-02-28
Allgenesis Receives Notice of Grant of Patent for Fusion Protein of VEGF Trap and Disintegrin in China
Read more
2021-11-25
Allgenesis Biotherapeutics Inc. – U.S. Patent Granted for Fusion Protein of VEGF Trap and Disintegrin
Read more
